Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19 Irani Thevarajan<sup>1,2#</sup>, Thi HO Nguyen<sup>3#</sup>, Marios Koutsakos<sup>3</sup>, Julian Druce<sup>4</sup>, Leon Caly<sup>4</sup>, Carolien E van de Sandt<sup>3,5</sup>, Xiaoxiao Jia<sup>3</sup>, Suellen Nicholson<sup>4</sup>, Mike Catton<sup>4</sup>, Benjamin Cowie<sup>1,2</sup>, Steven YC Tong<sup>1,2,6</sup>, Sharon R Lewin<sup>2,3,7</sup> and Katherine Kedzierska<sup>3</sup>\* **Affiliations** <sup>1</sup>Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria, Australia. <sup>2</sup>Doherty Department, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria, Australia. <sup>3</sup>Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville 3010, Victoria, Australia. <sup>4</sup>Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria, Australia. <sup>5</sup>Department of Hematopoiesis, Sanguin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066CX Amsterdam, Netherlands <sup>6</sup>Menzies School of Health Research, Charles Darwin University, Darwin, Australia. Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, 3010, Victoria, Australia \*Correspondence: kkedz@unimelb.edu.au; #authors contributed equally. Running title: COVID-19 and cellular immunity 

We report the kinetics of the immune response in relation to clinical and virological features of a patient with mild-to-moderate coronavirus disease-19 (COVID-19) requiring hospitalisation. Increased antibody-secreting cells, follicular T-helper cells, activated CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and IgM/IgG SARS-CoV-2-binding antibodies were detected in blood, prior to symptomatic recovery. These immunological changes persisted for at least 7 days following full resolution of symptoms, indicating substantial anti-viral immunity in this non-severe COVID-19.

45

46

47 48

49

50

51

52

53 54

5556

57

58

59

60

61

62

63

64 65

66

67

68 69

70 71

72

73

74

75

76

77 78

79

80

81

82

83 84

85

86

87

88

89

90

91

92

93

On 30/01/2020, a 47-year old woman from Wuhan, Hubei province, China presented to an emergency department in Melbourne, Australia. Her symptoms commenced 4 days earlier with lethargy, sore throat, dry cough, pleuritic chest pain, mild dyspnoea and subjective fevers (Fig.1a). She had travelled 11 days prior to presentation from Wuhan via Guangzhou to Australia. She had no contact with the Huanan seafood market or known COVID-19 cases. She was otherwise healthy, non-smoker, taking no medications. Clinical examination revealed a temperature of 38.5°C, pulse rate 120 beats/minute, blood pressure 140/80 mmHg, respiratory rate 22 breaths/minute, and oxygen saturation 98%, while breathing ambient air. Lung auscultation revealed bibasal rhonchi. At presentation day (d) 4, SARS-CoV-2 was detected by real-time reverse transcriptase polymerase-chain-reaction (rRT-PCR) from a nasopharyngeal swab specimen. SARS-CoV-2 was again detected at d5-6 from nasopharyneal. sputum and faecal samples, but was undetectable from d7 (Fg.1a). Blood C-reactive protein was elevated at 83.2, with normal lymphocyte counts (4.3x10<sup>9</sup>/L [range 4.0- $12.0 \times 10^9 / L$ ) and normal neutrophil counts  $(6.3 \times 10^9 / L)$  [range  $2.0 - 8.0 \times 10^9 / L$ ]). No other respiratory pathogens were detected. Her management was intravenous fluid rehydration without supplemental oxygenation. No antibiotics, steroids or antiviral agents were administered. Chest radiography demonstrated bibasal infiltrates at d5, which cleared on d10 (Fig.1b), and she was discharged to home isolation on d11. Symptoms resolved completely by d13 and she remained well at d20 post-onset of symptoms. Progressive increase in plasma COVID-19-binding IgM/IgG antibodies, from d7 until d20 was observed (Fig.1c).

There are currently no data defining immune responses leading to viral clearance and clinical resolution of COVID-19. We addressed this knowledge gap by analysing the breadth of immune responses in blood prior to patient recovery. As antibody-secreting cells (ASCs) are key for the rapid production of antibodies following viral Ebola infection<sup>1,2</sup>, influenza virus infection and vaccination<sup>2,3</sup>; and activated circulating follicular T helper (cTfhs) are concomitantly induced following influenza vaccination<sup>3</sup>, we first determined the frequency of CD3<sup>-</sup>CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs and CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup>PD1<sup>+</sup> cTfh responses at 3 days prior to symptomatic recovery. ASCs appeared in blood at the time of viral clearance at d7 (1.48%) and peaked on d8 (6.91%). Emergence of cTfhs occurred concurrently in blood at d7 (1.98%), with the frequency increasing on d8 (3.25%) and d9 (4.46%) (**Fig.2a**). The peak of both ASCs and cTfhs was markedly higher in the COVID-19 patient than the baseline controls levels healthy (average±SD:  $0.61\pm0.40\%$ 1.83±0.77%, respectively, n=5). Both ASCs and cTfhs were still prominently present at convalescence (d20) (4.54% and 7.14%, respectively; **Fig.2a**). Our study provides evidence on the recruitment of both ASCs and cTfhs in patient's blood whilst still

unwell and 3 days prior to resolution of symptoms, indicating their importance in anti-viral immunity towards SARS-CoV-2.

94

95

96 97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113 114

115

116

117

118

119

120 121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136 137

138 139

140

141

142

143

Since co-expression of CD38 and HLA-DR is well defined as the key phenotype of CD8<sup>+</sup> T-cell activation towards viral infections, we analyzed activation of CD8<sup>+</sup> Tcells by CD38/HLA-DR co-expression. In accordance with previous reports on Ebola and influenza<sup>1,4</sup>, CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression on CD8<sup>+</sup> T-cells rapidly increased from d7 (3.57%) to d8 (5.32%) and d9 (11.8%), with a decrease at d20 (7.05%) (**Fig.2b**). Furthermore, the frequency of CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression on CD8<sup>+</sup> Tcells in this patient was markedly higher than on CD8<sup>+</sup> T-cells in healthy individuals (1.47±0.50%, n=5), Similarly, CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression increased on CD4<sup>+</sup> T-cells between d7 (0.55%) and d9 (3.33%) in the patient, compared to healthy donors (0.63±0.28%, n=5), although at lower levels than CD8<sup>+</sup> T-cells. CD38<sup>+</sup>HLA-DR<sup>+</sup> T cells, especially within CD8<sup>+</sup> T-cells, produced higher amounts of granzymes A/B and perforin (~34-54% higher) than their parent (CD8<sup>+</sup> or CD4<sup>+</sup> populations, Fig.2b). Thus, the emergence and rapid increase in activated CD38<sup>+</sup>HLA-DR<sup>+</sup> T-cells, especially CD8<sup>+</sup>T-cells, at d7-9 preceded resolution of symptoms.

We also analysed CD16<sup>+</sup>CD14<sup>+</sup> monocytes, related to immunopathology, and activated HLA-DR<sup>+</sup>CD3 CD56<sup>+</sup>NK cells (**Fig.2c**). We detected reduced frequencies of CD16<sup>+</sup>CD14<sup>+</sup> monocytes in peripheral blood at d7-9 (1.29%, 0.43%, 1.47%, respectively), compared to healthy controls (9.03±4.39%, n=5). This might indicate efflux of CD16<sup>+</sup>CD14<sup>+</sup> monocytes from blood to the site of infection, which remained low at d20 (2.24%). Low levels of activated HLA-DR<sup>+</sup>CD3<sup>-</sup>CD56<sup>+</sup>NK cells were found in both the COVID-19 patient and healthy controls.

As high levels of pro-inflammatory cytokines/chemokines are predictive of severe clinical outcomes for influenza<sup>5</sup>, seventeen pro-inflammatory cytokines/chemokines were quantified in patient's plasma. We found low levels of monocyte chemoattractant protein-1 (MCP-1; CCL2), important for the recruitment of monocytes, T-cells and dendritic cells to the site of infection (Fig.2d). However, these MCP-1 levels were similar to healthy donors (22.15±13.81, n=5), patients infected with influenza A (IAV) and influenza B viruses (IBV) at d7-9 (33.85±30.12, n=5) and a patient with a known human coronavirus infection HCoV-229e (hCoV, 40.56). Substantial levels of RANTES (CCL5), involved in homing and migration of activated T-cells that express CCR5, were also detected in COVID-19 plasma but these were comparable to healthy donors (p=0.412), IAV/IBV-infected patients (p=0.310) and a hCoV-patient. Thus, in contrast to severe avian H7N9 disease with highly elevated IL-6 and IL-8, and intermediate IL-10, MIP-1β, IFN-γ<sup>5</sup>, minimal proinflammatory cytokines/chemokines were found in this patient with CoVID-19, even while symptomatic at d7-9.

Given that interferon-induced transmembrane protein-3 (IFITM3) single nucleotide polymorphism (SNP)-rs12252-C/C was linked to severe influenza<sup>5,6</sup>, we analysed the IFITM3- rs12252 SNP in this patient with COVID-19. Interestingly, the patient had the 'risk' IFITM3-rs12252-C/C variant (Fig.2e), associated with clinical compromise for 2009-pH1N1<sup>6</sup> and severe/fatal avian H7N9 disease<sup>5</sup>. As the relative prevalence of IFITM3-rs12252-C/C risk variant in a healthy Chinese population is 26.5% (data

from 1,000 genome project)<sup>5</sup>, further investigations of the IFITM3-rs12252-C/C allele

in larger cohorts of patients with COVID-19 and its correlation with disease severity is worth pursuing.

Collectively, our study provides novel contributions to the understanding of the breadth of the immune response during a non-severe case of COVID-19. This patient did not experience complications of respiratory failure, acute respiratory distress syndrome, did not require supplemental oxygenation and was discharged within a week of hospitalization, consistent with non-severe but clearly symptomatic disease. We provide evidence on the recruitment of immune populations (antibody-secreting B cells, follicular T-cells, activated CD4<sup>+</sup> and CD8<sup>+</sup> T-cells), together with IgM-IgG SARS-CoV-2-binding antibodies, in patient's blood prior to resolution of clinical symptoms. We propose that these immune parameters should be characterised in larger cohorts of patients with COVID-19 with different disease severity to understand whether they could be used to predict disease outcome and to evaluate new interventions to minimise severity and/or to inform protective vaccine candidates. Furthermore, our study indicates that robust multi-factorial immune responses can be elicited towards the newly-emerged SARS-CoV-2, and similar to the avian H7N9 disease', early adaptive immune responses might correlate with better clinical outcomes.

#### References

144

145

146 147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163164165

171

173174175

176

177

178

179

180

181

182

183

184

185

186

187 188

- 166 1. McElroy, A.K. et al. Proc Natl Acad Sci USA 112, 4719-4724 (2015).
- 167 2. Ellebedy, A.H. et al. Nat Immunol 17, 1226-1234 (2016).
- 168 3. Koutsakos, M. et al. Sci Transl Med **10** (2018).
- 169 4. Wang, Z. et al. Nat Commun 9, 824 (2018).
- 170 5. Wang, Z. et al. Proc Natl Acad Sci USA **111**, 769-774 (2014).
  - 6. Everitt, A.R. *et al.* **484**, 519-523 (2012).
- 172 7. Wang, Z. Nat Commun **6:** 6833 (2015).

**Fig.1.** Time course of clinical presentation and detection of SARS-CoV-2 in a range of clinical specimens and antibodies to SARS-CoV2 in blood. (a) Timeline of COVID-19; detection of SARS-CoV-2 virus in sputum, nasopharyngeal aspirates, faeces but not urine, rectal swab and whole blood. SARS-CoV-2 was quantified by real-time RT-PCR and the cycle threshold (Ct) is shown for each of the specimen. An increase in Ct value is consistent with a decrease in viral load. The assay limit of detection (LOD) threshold is Ct=45. Open circles: undetectable SARS-CoV-2; (b) Radiological improvement from admission to discharge from hospital. Anteroposterior chest radiographs on d5 (day of admission) and d10 following onset of symptoms; (c, d) Immunofluorescence antibody staining for the detection of IgG and IgM bound to SARS-CoV-2-infected vero cells using plasma (diluted 1:20) collected at d7-9 and d20 following onset of symptoms.

## Fig.2. Emergence of immune responses during non-severe symptomatic COVID-

- 189 19. Frequencies of (a) CD27<sup>hi</sup>CD38<sup>hi</sup> antibody-secreting cells (ASC; plasmablasts,
- 190 gated on CD3 CD19<sup>+</sup> lymphocytes) and activated ICOS PD1<sup>+</sup> follicular T helper
- 191 (Tfh) cells (gated on CD4<sup>+</sup>CXCR5<sup>+</sup> lymphocytes); (b) activated CD38<sup>+</sup>HLA-DR<sup>+</sup>
- 192 CD8<sup>+</sup> and CD4<sup>+</sup> T-cells; (c) lineage CD14<sup>+</sup>CD16<sup>+</sup> monocytes and activated HLA-DR<sup>+</sup>
- NK cells (gated on CD3 CD14 CD56 cells) detected by flow cytometry for blood

collected at d7-d9 and d20 following onset of symptoms and in healthy donors (median with IQ range); **(b)** Histograms and line graphs of granzymes A/B/K/M and perforin (Prf) staining of parent CD8<sup>+</sup> or CD4<sup>+</sup> T cells and activated CD38<sup>+</sup>HLA-DR<sup>+</sup>CD8<sup>+</sup>/CD4<sup>+</sup> T-cells are shown (bottom panels). **(d)** Plasma levels of proinflammatory cytokines/chemokines in COVID-19 patient at d7-9, healthy individuals (n=5, mean±SEM), patient with HCoV-229e and influenza-infected patients (n=5). **(e)** 'risk' IFITM3-rs12252 genotyping for the COVID-19 patient.

## **Acknowledgments**

194

195

196

197

198

199

200

201202203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221222223

224225226

227

228

229

230

231232

233

234

235

236

237238

The authors thank Prof Cameron Simmons for supporting the development of SETREP-ID, all the SETREP-ID investigators for their support and Australian Partnership for Preparedness Research for Infectious Disease Emergencies (APPRISE) for ongoing funding of SETREP-ID. We thank Dr Louise Rowntree for technical assistance. This work was funded by the Australian National Health and Medical Research Council (NHMRC) Investigator Grant to KK (#1173871). CES has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 792532 and University of Melbourne McKenzie Fellowship laboratory support. KK is supported by a NHMRC Senior Research Fellowship Level B (#1102792) and SRL is supported by an NHMRC Practitioner Fellowship and an NHMRC program grant. SYCT is supported by a NHMRC Career Development Fellowship (#1145033). XJ is supported by China Scholarship Council-University of Melbourne joint Scholarship. The authors wish to acknowledge our public health partners, and VIDRL's major funder, the Victorian Department of Health and Human Services without whom this work would not have been possible, and the clinical and laboratory staff involved in the care of this patient.

## **Online content**

#### **Author contribution**

IT, THON, MK, CES, LC, SN, XJ, JD, MK, BC, SYT, SRL, KK formulated ideas, designed the study and experiments; THON, MK, CES, LC, SN, XJ, JD performed experiments; THON, MK, LC, SN, JD analysed the experimental data, KK, IT, THON, SYT, BC, SRL wrote the manuscript. All authors reviewed the manuscript.

### **Competing interests**

The authors declare no conflict of interest. SRL's institution has received funding for investigator initiated research grants from Gilead Sciences, Merck, Viiv Healthcare and Leidos. She has received honoraria for participation in advisory boards and educational activities for Gilead Sciences, Merck, Viiv Healthcare and Abbvie.

#### Methods

# 239 Study design

- 240 The patient was enrolled through the Sentinel Travelers Research Preparedness
- 241 Platform for Emerging Infectious Diseases novel coronavirus substudy (SETREP-ID
- 242 coV). Sputum, nasopharyngeal aspirates, urine and faecal specimens as well as whole

- 243 blood in sodium heparin tubes were collected over the duration of illness and 9 days
- 244 post discharge for quantitative virology, immunology and assessment of host gene
- 245 factors. Human experimental work was conducted according to the Declaration of
- 246 Helsinki Principles and according to the Australian National Health and Medical
- 247 Research Council Code of Practice. Participants provided written informed consent
- prior to the study. The study was approved by the Royal Melbourne Hospital (HREC
- 249 Reference number: HREC/17/MH/53 and HREC/15/MonH/64/2016.196) and
- University of Melbourne (ID #1442952.1 and #1443389.4) Human Research Ethics
- 251 Committees.

252253

254

255

256

257

258

259

260

261262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280 281

282

283

284

285

286

287

288

289

290291

#### **Generation of SARS-CoV-2 cDNA**

RNA was extracted from 200µL from patient's swabs (nasopharyngeal, rectal, throat in VTM), sputum, urine, faeces and whole-blood samples using the QIAamp 96 Virus QIAcube HT Kit (Qiagen, Hilden, Germany). Reverse transcription was performed using the BioLine SensiFAST cDNA kit (Bioline, London, United Kingdom). Total reaction mixture of 20µl contained 10µL of the RNA extract, 4µl of 5x TransAmp buffer, 1µl of Reverse Transcriptase and 5µl of Nuclease free water. Reactions were incubated at 25°C for 10 min, 42°C for 15 min, 85°C for 5 min.

## Nested SARS-CoV-2 RT-PCR and Sanger sequencing

A PCR mixture containing 2µl cDNA, 1.6µl of 25 mM MgCl<sub>2</sub>, 4µl of 10x Qiagen Taq Buffer, 0.4µl of 20mM dNTPs, 0.3µl of Taq polymerase (Qiagen, Hilden, Germany) and 2µl of 10µM primer pools as described<sup>11</sup>. The first round included the forward (5'-GGKTGGGAYTAYCCKAARTG-3') and GGKTGGGAYTAYCCKAARTG-3') primers. Cycling conditions were 94°C for 10 min, followed by 30 cycles of 94°C for 30s, 48°C for 30s and 72°C for 40s, with a final extension of 72°C for 10 min. PCR product (2µl) was used in the second round PCR reaction which included the forward (5'-GGTTGGGACTATCCTAAGTGTGA-3') and reverse (5'-CCATCATCAGATAGAATCATCAT-3') primers. Cycling conditions were 94°C for 10min, followed by 40 cycles of 94°C for 30s, 50°C for 30s and 72°C for 40s, with a final extension of 72°C for 10 min. PCR products had an expected size of approximately 440bp on a 2% agarose gel. The PCR products were purified using ExoSAP-IT (Affymetrix, Santa Clara, CA, USA) and sequenced using an Applied Biosystems SeqStudio Genetic Analyzer (Life Technologies, Carlsbad, CA, USA) using Big Dye Terminator 3.1 (Life Technologies, Carlsbad, CA, USA) and Round 2 PCR primers above. SARS-CoV and 229e-CoV cDNA were used as positive controls.

## Detection of SARS-CoV-2 using TaqMan Real-time RT-PCR E-gene assay

TaqMan RT-PCR assay comprised of 2.5μl cDNA, 10μl Primer Design PrecisonPLUS qPCR Master Mix 1μM Forward (5'-ACA GGT ACG TTA ATA GTT AAT AGC GT -3'), 1μM Reverse (5'-ATA TTG CAG CAG TAC GCA CAC A-3') primers and 0.2μM Probe (5'-FAM-ACA CTA GCC ATC CTT ACT GCG CTT CG-NFQ-3') targeting the Betacoronavirus E-gene<sup>1</sup>. The real-time RT-PCR assay was performed on an Applied Biosystems ABI 7500 Fast Real-time PCR machine (Applied Biosystems, Foster City, CA, USA) with cycling conditions 95°C for 2min, 95°C for 5s, 60°C for 24s. SARS-CoV cDNA (Ct~30) was used as a positive control.

## **IFITM3 SNP analysis**

- 292 PCR was performed on genomic DNA extracted from patient's granulocytes (using
- 293 QIAamp DNA Mini Kit, QIAGEN) to amplify the exon 1 rs12252 region using
- 294 forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-
- 295 CATACGCACCTTCACGGAGT-3') primers<sup>2</sup>.

### Cytokine analysis

- Patient's plasma was diluted 1:4 before measuring cytokine levels (IL-2, IL-4, IL-6,
- 299 IL-8, IL-10, IL-12p70, IL-17A, IL-1β, IFN-α, MIP-1α, MIP-1β, MCP-1,
- 300 CD178/FasL, granzyme B, RANTES, TNF, IFN-γ) using the Human CBA Kit (BD
- 301 Biosciences, San Jose, California, USA). For RANTES, sera/plasma was also diluted
- to 1:50. Healthy donors D6-D10 were of a mean age of 32 (range 22-55 years; 40%
- 303 females).

296297

304 305

318

319320

321

322

323

324

325

326

327

328

329

330

331332

337338339

340

## Whole blood staining and flow cytometry

306 Fresh whole blood (200µl per stain) was used to measure CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup>PD1<sup>+</sup> 307 follicular T cells (Tfh) and CD3<sup>-</sup>CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> antibody-secreting B cell (ASC; plasmablast) populations as described<sup>3</sup> as well as activated HLA-308 309 DR<sup>+</sup>CD38<sup>+</sup>CD8<sup>+</sup> and HLA-DR<sup>+</sup>CD38<sup>+</sup>CD4<sup>+</sup> T cells, inflammatory CD14<sup>+</sup>CD16<sup>+</sup> and 310 conventional CD14+ monocytes, activated HLA-DR<sup>+</sup>CD3 CD56<sup>+</sup> NK cells, as per the 311 specific antibody panels (Supplementary Table 1; gating strategy is presented in 312 Supplementary Fig.1). After the whole blood was stained for 20 mins at room 313 temperature (RT) in the dark, samples were lysed with BD FACS Lysing solution, 314 washed and fixed with 1% PFA. Granzymes/perforin staining (patient d20) was 315 performed using the eBioscience Foxp3/Transcription Factor Staining Buffer Set after 316 the lysis step. All the samples were acquired on a LSRII Fortessa (BD). Flow 317 cytometry data were analyzed using FlowJo v10 software. Healthy donors D1-D5

#### Detection of IgG and IgM antibodies in SARS-CoV-2 -infected vero cells

were of a mean age of 35 (range 24-42 years, 40% females).

Immunofluorescence antibody tests for the detection of IgG and IgM were performed using SARS-CoV-2-infected vero cells that had been washed with PBS and methanol/acetone fixed onto glass slides. Ten μL of a 1/20 dilution of patient plasma in PBS from days 7, 8, 9 and 20 were incubated on separate wells for 30 mins at 37°C, then washed in PBS and further incubated with 10μL of FITC-conjugated goat anti-human IgG and IgM (Euroimmun, Lűbeck, Germany) before viewing on a EUROStar III Plus fluorescent microscope (Euroimmun). Prior to detection of IgM antibodies, samples were pre-treated with RF-SorboTech (Alere, Rűsselsheim, Germany) to remove IgG antibodies and rheumatoid factors, which may cause falsenegative and false-positive IgM results, respectively.

#### Reference

- 333 1. Corman, V.M. et al. Euroservaillance 25, doi: 10.2807/1560-
- 334 7917.ES.2020.25.3.2000045 (2020).
- 335 2. Clemens, E.B. et al. Immunol & Cell Biol 94, 367-377 (2016).
- 336 3. Koutsakos, M. et al. Sci Transl Med **10** (2018).

# Data availability

The data that support the findings of this study are available from the corresponding author upon request. Raw FACS data are shown in the manuscript.

Supplementary Table 1. Whole blood immunophenotyping and antibody panels used in our immune assays.

**Supplementary Figure 1. Flow cytometry gating strategy for immune cell subsets.** Gating panels are shown for **(a)** CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs and activated ICOS<sup>+</sup>PD1<sup>+</sup> Tfh cells; **(b)** activated CD38<sup>+</sup>HLA-DR<sup>+</sup> CD8<sup>+</sup> and CD4<sup>+</sup> T-cells, activated HLA-DR<sup>+</sup> NK cells and lineage CD14<sup>+</sup>CD16<sup>+</sup> monocytes; and **(c)** granzymes (GZM) A/B/K/M and perforin expression on CD8<sup>+</sup>/CD4<sup>+</sup> T-cells and activated CD38<sup>+</sup>HLA-DR<sup>+</sup> CD8<sup>+</sup>/CD4<sup>+</sup> T-cells.




Figure 1. Thevarajan et al




Figure 2. Thevarajan et al